nach oben

Abdominal Radiology

Erschienen in:

01.01.2018

LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma

verfasst von: Kathryn J. Fowler, Theodora A. Potretzke, Thomas A. Hope, Eduardo A. Costa, Stephanie R. Wilson

Erschienen in: Abdominal Radiology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

LI-RADS v2017 introduces major changes to the diagnostic criteria for LR-M observations to better guide radiologists in the use of this malignant category designation. LR-M is intended to preserve the specificity of the LI-RADS algorithm for diagnosis of HCC while not losing sensitivity for diagnosis of malignancy. The purpose of this paper is to provide a brief background on LR-M, discuss the diagnostic criteria new to v2017, special considerations for its application, and management implications.

Siegel R, et al. (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30

Khan SA, et al. (2005) Cholangiocarcinoma. Lancet 366(9493):1303–1314CrossRefPubMed

Ercolani G, et al. (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252(1):107–114CrossRefPubMed

Tyson GL, El-Serag HB (2011) Risk factors for cholangiocarcinoma. Hepatology 54(1):173–184CrossRefPubMedPubMedCentral

Shaib YH, et al. (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128(3):620–626CrossRefPubMed

Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7(3):462–503CrossRefPubMed

Goodman ZD, et al. (1985) Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55(1):124–135CrossRefPubMed

Jarnagin WR, et al. (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94(7):2040–2046CrossRefPubMed

Ng IO, et al. (1998) Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol 13(1):34–40CrossRefPubMed

10.

Choi SH, et al. (2016) Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51(8):483–490CrossRefPubMed

11.

Chen N, et al. (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15(1):49–59CrossRefPubMed

12.

Darnell A, et al. (2015) Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275(3):698–707CrossRefPubMed

13.

Fowler KJ, et al. (2013) Validation of organ procurement and transplant network (OPTN)/united network for organ sharing (UNOS) criteria for imaging diagnosis of hepatocellular carcinoma. Transplantation 95(12):1506–1511CrossRefPubMed

14.

Wald C, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382CrossRefPubMed

15.

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022CrossRefPubMedPubMedCentral

16.

Park MJ, et al. (2013) Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 37(6):872–881CrossRefPubMed

17.

Chong YS, et al. (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67(8):766–773CrossRefPubMed

18.

Kim R, et al. (2016) Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol 26(6):1808–1817CrossRefPubMed

19.

Rimola J, et al. (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50(3):791–798CrossRefPubMed

20.

Asayama Y, et al. (2015) Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol 21(2):96–104CrossRefPubMedPubMedCentral

21.

Joo I, et al. (2016) Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging 44(5):1330–1338CrossRefPubMed

22.

Huang B, et al. (2016) Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging. Radiology 281(1):150–157CrossRefPubMed

23.

Park HJ, et al. (2016) Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol 26(9):3102–3111CrossRefPubMed

24.

Hwang J, et al. (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36(4):881–889CrossRefPubMed

25.

Peporte AR, et al. (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82(3):e101–e106CrossRefPubMed

26.

Kang Y, et al. (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264(3):751–760CrossRefPubMed

27.

Tsunematsu S, et al. (2015) Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdom Imaging 40(6):1492–1499CrossRefPubMed

28.

Ciresa M, et al. (2015) Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features. Eur Rev Med Pharmacol Sci 19(15):2786–2797PubMed

29.

Potretzke TA, et al. (2016) Imaging features of biphenotypic primary liver carcinoma (Hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207(1):25–31CrossRefPubMed

30.

Fowler KJ, et al. (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201(2):332–339CrossRefPubMed

31.

Fukukura Y, et al. (1997) Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 21(1):52–58CrossRefPubMed

32.

Sanada Y, et al. (2005) A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 32(3):185–195CrossRefPubMed

33.

Wells ML, et al. (2015) Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging 40(7):2293–2305CrossRefPubMed

34.

Alustiza JM, et al. (2007) Iron overload in the liver diagnostic and quantification. Eur J Radiol 61(3):499–506CrossRefPubMed

35.

Yuan MX, et al. (2016) Factors affecting the enhancement patterns of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) and their pathological correlations in patients with a single lesion. Ultraschall Med 37(6):609–618PubMed

36.

Kong WT, et al. (2014) Value of wash-in and wash-out time in the diagnosis between hepatocellular carcinoma and other hepatic nodules with similar vascular pattern on contrast-enhanced ultrasound. J Gastroenterol Hepatol 29(3):576–580CrossRefPubMed

37.

Wildner D, et al. (2014) Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med 35(6):522–527CrossRefPubMed

Titel: LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma
verfasst von: Kathryn J. Fowler
Theodora A. Potretzke
Thomas A. Hope
Eduardo A. Costa
Stephanie R. Wilson
Publikationsdatum: 01.01.2018
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 1/2018
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-017-1196-2

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma

Abstract

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Hepatocarcinogenesis and LI-RADS

Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis

LI-RADS® algorithm: CT and MRI

LI-RADS and transplantation for hepatocellular carcinoma

LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents

Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie